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Abstract
While improved drug regimens have greatly enhanced outcomes for patients with chronic viral
infection, antiviral therapy is still not ideal due to drug toxicities, treatment costs, primary drug
failure and emergent resistance. New antiviral agents, alternative treatment strategies and a better
understanding of viral pathobiology, host responses and drug action are desperately needed.
Interferon (IFN) and ribavirin, are effective drugs used to treat hepatitis C (HCV), but the
mechanism(s) of their action are uncertain. Error catastrophe (EC), or precipitous loss of
replicative fitness caused by genomic mutation, is postulated to mediate ribavirin action, but is a
deeply flawed hypothesis lacking empirical confirmation. Paradoxically ribavirin, a proven RNA
mutagen, has no impact on HCV viraemia long term, suggesting real viruses, replicating in-vitro, as
opposed to mathematical models, replicating in-silico, are likely to resist EC by highly selective
replication of fit (~consensus sequence) genomes mediated, in part, by replicative homeostasis
(RH), an epicyclic mechanism that dynamically links RNApol fidelity and processivity and other viral
protein functions. Replicative homeostasis provides a rational explanation for the various
responses seen during treatment of HCV, including genotype-specific and viral load-dependent
differential response rates, as well as otherwise unexplained phenomena like the transient
inhibition and rebound of HCV viraemia seen during ribavirin monotherapy. Replicative
homeostasis also suggests a primarily non-immunological mechanism that mediates increased
immune responsiveness during treatment with ribavirin (and other nucleos(t)ide analogues),
explicating the enhanced second-phase clearance of HCV ribavirin promotes and, thus, the
apparent immunomodulatory action of ribavirin. More importantly, RH suggests specific new
antiviral therapeutic strategies.
1.0 Background
1.1 Disease prevalence
Chronic viral infection, notably with the human immun-
odeficiency virus (HIV), and hepatitis B (HBV) and C
(HCV), as well as other viruses like Ross River and West
Nile Viruses, is a global public health problem that affects
perhaps a billion people world-wide. About 500 million
people are infected with HBV, while perhaps 200 million
more are have chronic HCV. Annually, about 2 million
people with CVH die prematurely due to liver failure or
hepatocellular carcinoma (HCC). Hepatitis C is the most
common cause of chronic hepatitis and cirrhosis in the US
[1], and other western nations, and is now the most com-
mon indication for liver transplantation worldwide. Con-
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servative estimates suggest the numbers requiring
transplantation for HCV will increase 5 fold in the US –
that is, well in excess of existing organ availability – over
the next two decades [2] unless more effective therapies
for HCV are found urgently. Currently, at least 50 million
people worldwide are infected with HIV, of whom about
one million will die from AIDS and AIDS-related compli-
cations each year, with numbers increasing steadily.
Although HIV, like HBV, now predominantly affects the
developing world, about 50,000 new cases will be diag-
nosed in the United States this year.
1.2 Antiviral therapy
Antiviral therapy remains extremely problematic: While
highly active antiretroviral therapy (HAART) has dramati-
cally slowed disease progression, and has significantly
improved outcomes for HIV infected individuals receiving
therapy, significant adverse reactions (SARs) are common.
Similarly, although treatment of CVH has improved
greatly during the past 5 years, about 50% of those
infected with genotype 1 HCV will fail to clear virus, even
with optimal use of the best currently available treatment
regimen(s) in maximally compliant patients [3,4]. The
options for those who fail therapy are currently very lim-
ited. For hepatitis B (HBV) viral resistance to
nucleos(t)ide therapy is extremely common and develop-
ment of multi-drug resistant strains is an increasingly
important problem [5]. Nucleos(t)ide analogues are also
relatively non-specific and inhibition of normal cellular
enzymes, causing impaired genomic and mitochondrial
DNA and cellular RNA metabolism, resulting in genomic
mutagenesis and mitochondrial toxicity [6], for example,
are major potential concerns with this class of drug. Many
patients also experience debilitating side effects from
treatments that are often required life-long, while others
are unable to tolerate, or are poorly compliant with, com-
plex antiviral drug regimens that are expensive, and
beyond the financial reach of many patients, especially in
those countries that bear the greatest burden of disease.
More effective, specific and cheaper antiviral therapies are
urgently needed.
2.0 Host-virus interactions
Despite enormous recent advances in molecular virology
and immunology the pathobiology of chronic viral infec-
tions is still incompletely understood. In particular, the
reason(s) some individuals clear virus, while others
remain infected and ultimately develop disease is/are
unknown. Many clinical features, including patient age
and other demographic data, duration of disease [7],
genetic background [8] metabolic factors [9] (including
body mass index, glucose tolerance and iron overload)
and so forth have some influence on the outcome of
patients treated for HCV, though few of these factors are
easily modified therapeutically. Significant research effort
has therefore been directed at defining the principle
genetic, biochemical and immunological characteristics
of patients that predict either viral clearance or chronic
viral infection in the hope these factors can be targeted
therapeutically. Observations that stronger specific CD4/
CD8 immune responses with CD4+  T-helper (TH1)
cytokine profiles, for example, are found more frequently
in patients with self limiting viral infections than in those
who develop chronic viral carriage [10,11] has directed
attention to the balance of CD4+ TH1/TH2 lymphocyte
responses and resulted in attempts to enhance immune
responsiveness therapeutically [12,13], in the belief viral
clearance will be enhanced long term by these therapies.
This strategy has yet to prove beneficial.
3.0 Virus-host interactions
Viruses, like other self-replicating molecules, are primarily
concerned with producing more viruses. The survival of
viruses, as obligate intracellular parasites, over a geologi-
cal time scale, implies the development of strategies that
allow them to effectively paralyse or to circumvent cellular
defence mechanisms – including the innate immune sys-
tem and those defences preventing cell entry – while
maintaining those metabolic processes essential for viral
replication; cell membrane integrity, cell homeostasis and
the apparatus essential for protein synthesis. Long term,
those viruses capable of inducing a chronic vegetative cel-
lular state and subverting the cellular machinery necessary
for their replication will be selected for, while those caus-
ing premature (that is, before viral replication is com-
plete) lethal cell injury will not. Observed viral adaptation
[14] and rapid development of antiviral drug resistance
[5] over much shorter time-scales confirms their evolu-
tion is highly dynamic. As discussed previously [15], the
ineluctable consequence of an RNA virus quasispecies is a
protein quasispecies, and these proteins will possess a
near-infinite spectrum of phenotypes, at least potentially.
It is therefore entirely unsurprising that viruses with
nucleic acid sequences coding for proteins that block
apoptosis [16], interfere with the Toll-like receptors
(TLRs) that mediate interferon signalling and expression
of many other host genes [17] and interrupt other innate
cell defense pathways, including interferon [IFN] regula-
tory factor [IRF], Janus activated kinase (Jak1), signal
transducer and activator of transcription proteins 1 and 2
(STAT1/2), and inducible nitric oxide synthase [iNOS])
[18], protein kinase (PKR), and so forth, have been
selected for and flourish. The nature of viral protein qua-
sispecies make it entirely predictable that these viral anti-
cell defence mechanisms would act at multiple levels
against each pathway, as the actions of HCV proteins
against interferon signalling confirm [19-21], and in infi-
nitely subtle ways against defence mechanisms as yet uni-
dentified. While these viral defence mechanism(s)
represent potentially important therapeutic targets – inVirology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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particular the serine protease [21-24] – one would antici-
pate resistance to these therapies developing rapidly due
to the multiple layers of redundancy of anti-cell-defence
mechanisms viruses possess, as is seen with HIV and
increasingly with HBV [5] therapy. Furthermore, it is
entirely to be expected these resistant strains will be
selected for by drug treatment.
4.0 Viral responses to therapy
At present, the only proven treatment for HCV is Inter-
feron alpha (IFN-∝) (IFN-∝2a, IFN-∝2b and consensus
interferon) or combination IFN-∝, now usually adminis-
tered as long-acting pegylated [3] or albumin-conjugated
[25] forms, with ribavirin, as combination therapy.
Although the viral kinetics observed in individual patients
may not be as clean as those represented schematically
here (Figure 1), four main patterns of response are seen; i)
Non-responders, in whom levels of HCV RNA appear
completely unchanged by therapy, ii) the sustained viral
response (SVR), defined by sustained absence of HCV
RNA from serum long after therapy is withdrawn, iii)
Relapsers, in whom virus is documented to be eradicated
from serum during therapy, but in whom withdrawal of
therapy results in recurrence and iv) a fourth group, often
grouped with non-responders [26], but possibly better
classified as partial responders; In these patients the HCV
RNA clearly falls during treatment, sometimes to undetec-
table levels, indicating some response of virus to therapy,
but rebounds back to pre-treatment levels (and some-
times beyond) despite adherence to ongoing therapy. This
rebound in HCV RNA levels implies a compensatory viral
homeostatic response – a potentially significant therapeu-
tic target, as previously discussed [27] – suggesting differ-
entiation of this group from true non-responders is
conceptually important. The viral factors known to deter-
mine the likelihood of response to antiviral therapy
include a) viral genotype b) viral load c) RNA quasispecies
diversity and d) acute hepatitis.
5.0 Clinical importance of viral genotype
A large number of clinical trials confirm that the single
most important determinant of HCV clearance in
response to treatment is viral genotype [28-34]. Briefly,
for all patients with HCV genotype 1 optimal combina-
tion pegylated interferon/ribavirin therapy for 48 weeks
will result in a SVR of about 50% [3,35], while for geno-
type 2 about 90% of patients will clear virus long-term
using the same treatment regimen for 24 weeks [36-38].
Patients with genotypes 2 or 3 respond more promptly
and require shorter duration of treatment than patients
infected with genotype 1 [33,39] or 4 [40]. As studies of
the treatment of chronic viral hepatitis, by definition, are
conducted in patients whose underlying innate, humoral
and cellular (including TH1/TH2 profiles) antiviral
responses do not permit spontaneous viral clearance,
those patients with less effective immune responses –
assuming, momentarily, normal population-based varia-
tions in those responses have any relevance whatsoever to
whether or not viral clearance occurs – are preferentially
selected and are over-represented in these trials.
Consider the following thought experiment: A large ther-
apeutic trial is conducted in a population where the point-
prevalence of genotypes 1 and 2 HCV is equal and no
other genotypes are represented. If 2000 patients with
chronic HCV are randomly selected, and treated with
pegylated interferon/ribavirin for one year, at the comple-
tion of the study roughly 500/1000 patients with type 1
HCV will remain infected, while ~900 of the ~1000
patients with type 2 HCV will experience SVR. As the virus
genotype with which a patient becomes infected is a ran-
dom function of the point-prevalence of that genotype in
the background population with which that individual
interacts, and is completely independent of any underly-
ing patient characteristic, the enormous differences in out-
come seen in this trial will occur irrespective of any
underlying human leukocyte antigen (HLA) type [41],
cytokine polymorphisms [42], CD4+ TH1/TH2 lymphocyte
responses [43], or any other genetic, metabolic or bio-
chemical feature of the host, suggesting the genotype-spe-
cific outcome following treatment with interferon/
ribavirin is almost purely a consequence of interaction(s)
between the virus and the therapy, and that other factors
are, comparatively, irrelevant for the vast majority of
patients. As it is further likely that other viral factors such
as pre-treatment viral load [3,44-46] and, possibly, qua-
sispecies complexity and diversity present prior to therapy
[47-49] (vide infra) will account for at least some of
patients with genotype 2 who do not experience SVR, it is
clear viral factors rather than any host attributes, are the
primary determinants of SVR and non-response. Why
should the genotype of HCV (and probably other viruses
[50]) be important and determine response to antiviral
therapy?
6.0 Evoutionary importance of genotype
The primordial transition from simple chemical solutions
to organic polymers through to the genesis of biological
complexity and the origins of life as we now know it was
contingent on the emergence of self-organizing and-self
replicating molecules. Irrespective of whether Eigen [51]
is correct that RNA was the original building block on
which all subsequent biological complexity developed,
the critical problem confronting self-replicating mole-
cules, of any form, is replication, more specifically, repli-
cative fidelity. Unless replication is near-perfect,
accumulation of 'genetic' errors results in inexorable dete-
rioration until all useful organization – "error catastro-
phe" – is lost. Eigen demonstrated that error catastrophe
occurs if the product of the 'genome' size (N, strictly, theVirology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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Classical patterns of HCV response to IFN/ribavirin (A), modified from [26], demonstrating virological non-response (black line 
●), partial response (blue line ), relapse (green ▲) and sustained virological response, SVR (red  ) Figure 1
Classical patterns of HCV response to IFN/ribavirin (A), modified from [26], demonstrating virological non-response (black line 
●), partial response (blue line ), relapse (green ▲) and sustained virological response, SVR (red  ). (B) HCV RNA 
response to Interferon (blue line), showing the rapid reduction in HCV RNA of phase 1 clearance followed by slow steady 
decline typical of phase 2 clearance, and during ribavirin therapy (red lines) in 2 representative individuals (B3, B6) reported by 
Pawlotsky et al [78]. Note moderate decrease in HCV RNA (-1.5 logs) in B3 (▲), but preceding slight increase (to +0.17 log) 
and persistent increase (to +0.25 log) in B6 ( ).
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number of bits of information coded by the system) and
the error rate of copying (ε, strictly, the rate information is
lost during each round of replication) exceeds log S, where
S is the selective advantage the replicative milieu imparts
to error-free molecules over those containing errors, that
is:
Nε < log S   Equation 1.
Meaning, if the rate information is lost during replication
exceeds the rate at which it is concentrated by any selective
advantage these molecules possess, error catastrophe
occurs. Because the selective advantage of any single
mutation is unlikely to be enormous, log S is unlikely to
greatly exceed unity (1), therefore ε cannot be much larger
than N-1. That is, for a genome of 100 'bases' replicative
stability requires any replicase (ribozyme, protein or
whatever) cannot have less fidelity than 10-2 errors/base
synthesized, and molecules of greater length (as would be
required to encode any biologically meaningful informa-
tion) would need progressively more faithful polymerases
to prevent genomic disorganization. Eigen suggested this
problem could be circumvented by the emergence of
molecular co-operation and hypercycles [52,53]. Clearly
finding Eigen's hypercycles of co-operative RNA mole-
cules conceptually troubling Niesert et al [54]., dissected
the hypercycle theory mathematically and demonstrated
three other 'catastrophes' – selfish RNA (parasitism),
hypercycle short circuiting and stochastic population col-
lapse, any of which can result in molecular extinction –
that beset populations of self replicating molecules, espe-
cially when molecular size and complexity increase.
Another major problem exists; although greatly increased
replicative fidelity is certainly necessary to ensure stable
replication of biologically relevant macromolecules, it is
insufficient; the problem is 'self'. By definition, self-repli-
cating molecules need to replicate themselves, and not
competitor molecules, hence mechanisms to distinguish
'self' from 'non-self' molecules are required, and this is
increasingly problematic once polymer size and complex-
ity increase and molecular co-operation and specializa-
tion is required and invoked; How does the replicase
recognise which molecule to copy? Self-replicating mole-
cules sail between the Scylla of lethal mutation and the
Charybdis of population collapse [54] and, therefore,
need to develop mechanism(s) that i) ensure adequate
fidelity ii) allow differentiation of self from non-self mol-
ecules; that is, permit recognition of geno-'type' to ensure
preferential self replication. iii) prevent molecular parasit-
ism and selfish genetic replication (broadly, to ensure the
'genetic quality' of the molecules to be replicated) and iv)
prevent stochastic population collapse. One imaginable
mechanism – replicative homeostasis (RH) – links the
functional output of the replicase epicyclically as both
negative and positive feedback to modulate the replicase
functions – processivity and fidelity (Figures 2, 3) – and in
a manner that dictates effective replication requires co-
operative interactions between multiple elements spa-
tially separated on the genome. Replication contingent
upon recognition of, and response to, complex three-
dimensional complementarities between the polymerase
and envelope proteins, and the polymerase and transcrip-
tion initiation sequences of the 5'UTR of RNA molecules,
constitutes a very sophisticated encryption technique that
maximises the probability only 'self' (i.e. homotypic)
molecules will be replicated, and effectively assays the
functional integrity and quality of the entire viral genome,
and its cognate proteins, as well as minimising the proba-
bility that either hypercycle short circuits or stochastic col-
lapse occur. Once self-replicating molecules emerge,
however, any replicative infidelity at all ensures multiple
molecular species will arise, and these different species
must compete for finite resources in the fitness landscape.
As Spiegleman and Orgel suggested originally [55], mole-
cules that develop reproductive strategies that maximise
replication of "self" genes, while thwarting propagation of
"rival" genes will proliferate at the expense of those that
do not. Thus, the intense thermodynamically driven com-
petition for survival causes self-replicating molecules to
develop inexorably more complex, subtle and metaboli-
cally expensive strategies to ensure the genomes they are
replicating (and with) are 'self', optimal quality (~consen-
sus sequence) and fit, and to guard against rival genomes
parasitizing or otherwise thwarting 'self'-replication.
These incrementally more sophisticated strategies include
acquisition of double RNA strands, DNA, protein-nucleic
acid symbiosis, cell walls, receptor polymorphisms,
motility, multicellularity, innate cellular defences, epista-
sis, lekking and other behaviours, language and money.
Protein-nucleic acid symbiosis is clearly critical for HCV
to function, but it does raise the question; Which of the
competing self-replicating molecules, the polymerase or
the RNA, conducts the HCV orchestra? Is it the RNA,
directing synthesis of RNApol to produce more RNA, or is
it, as seems more likely, the RNA polymerase that subtly
manipulates and directs its RNA(s) to produce the viral
shells necessary for production of more RNApol? In this
light is it possible prions are just primitive RNApol or
RNApol modulating proteins that simply highjack cellular
RNAs coding for cellular RNApol cuckolding them into
producing more prion protein?
7.0 Replicative Homeostasis
The mechanism of RH has been described in detail previ-
ously [27] but, in brief, it is proposed to result from differ-
ential interactions of wild-type (wt) and variant (mt)
envelope and envelope related proteins on RNApol in a
series of feedback epicycles that link RNApol functions
fidelity and processivity, RNA replication and viral protein
synthesis, structure and function (Figures 2, 3), such that,Virology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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Selective replication of fit (~consensus sequence) genomes Figure 2
Selective replication of fit (~consensus sequence) genomes. If high-level genomic replication by RNApol is contingent on recog-
nition of appropriate 5'UTR sequences by RNApol (i) and full length genomic transcription (ii) and ribosomal (R) translation of 
functional (f) polyprotein encoding both fRNApol and fEnvelope, then replication is an extremely effective test of genomic 
integrity (panel A) that powerfully selects for fit genomes and self genotypes. Inappropriate 5'UTR sequences (i) or truncation 
of transcription (ii), or synthesis of functionally defective mutant (mt) RNApol or Envmt sequences cause inefficient or abrogated 
replication, powerfully selecting against defective genomes, therefore resisting EC, as well as reducing the likelihood of replicat-
ing viruses of other genotypes.
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in general terms, excess production of mutant envelope
proteins, reflecting inadequate replicative fidelity, interact
with RNApol to increase its fidelity and reduce processivity,
while excess production of wild type (consensus
sequence) envelope sequences, reflecting overly faithful
replication (rendering the virus susceptible to immune-
mediated clearance or destruction through attenuation
and loss of replicative plasticity), interact with RNApol
causing decreased fidelity. The ineluctable consequence of
these interactions is the formation of highly stable, but
reactive equilibria that permit viruses to respond rapidly
to adverse changes to their conditions (e.g. immune rec-
ognition of dominant epitopes) and changing characteris-
tics (e.g. evolving receptor polymorphisms) of their hosts.
Several independent lines of evidence strongly suggest
that RH is mediated in HCV by interactions between the
E2 protein, with probable contribution from P7 that likely
'fine-tunes' RNApol modulation in a manner similar to
that proposed for HIVnef [56], and the interferon sensitiv-
ity region (ISDR) of NS5A and the thumb domain of the
RNA-dependent RNA polymerase from NS5B. First, these
regions are obviously important for genotype-specific
virus related functions; HCV genotypes characteristically
Mechanism of replicative homeostasis Figure 3
Mechanism of replicative homeostasis. (A) High concentrations of consensus sequence Envwt (blue, A) favour high affinity 
Envwt:RNApol interactions that out-compete variant forms (Envmt, red), and alter RNApol conformation that increase RNApol 
processivity and reduce fidelity, thus increasing the relative output of variant RNAs (red). Subsequent ribosomal (R, green) 
translation increases concentration of Envmt (red), relative to Envwt, reverting the system to equilibrium. Relative excess of 
Envmt (B, red) out-compete Envwt (blue) for interactions with RNApol, favouring Envmt:RNApol, and blocking Envwt:RNApol inter-
actions again altering RNApol conformation, the Envmt:RNApol complexes decrease RNApol processivity and increase fidelity, 
increasing output of wild-type RNAs. Subsequent increased translation of Envwt relative to Envmt restores the equilibrium.
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vary in length, with genotype 1 typically comprising 9030
to 9042 nucleotides, genotype 2 has 9099 and genotype 3
9063 nucleotides. The nucleotide insertions or deletions
responsible for these genotype-specific differences are
found within the E2 and NS5 portions of the genome
[57]. Second, while hypervariable regions within the E2
proteins evolve very rapidly [57], other regions of it are
tightly genotype-constrained and contain several highly
conserved amino acids and even in areas less obviously
invariant, the amino acid substitutions appear non-ran-
dom [58-60]. As we argued previously [61], this must
indicate an important, and genotype-specific, viral func-
tion; different sequences of these regions are clearly ade-
quate for virus-host interactions for other genotypes,
hence these genotype-specific regions of E2 must have
interact with other viral structures. Third, and while this is
controversial [62], evidence suggests sequence variability
in both the NS5A ISDR [63] and NS5B [64] and the HCV
E2 [65] is predictive of both response to interferon and
viral load [64]. Fourth, in chimpanzees persistent HCV
infection develops only in animals developing anti-enve-
lope (E2) antibodies, whereas failure to produce anti-E2 is
associated with viral clearance [66,67], intuitively a highly
paradoxical result difficult to rationalize unless E2 pro-
teins are important for HCV replication. Fifth, HCV chi-
meras heterotypic for p7, a 63 aa hydrophobic protein
encoded between E2 and NS2, are non-viable, indicating
P7 has critical genotype-specific interactions with "RNA/
protein sequences in other genome regions" [68]. Finally,
PKR, induced by IFN [69], is also known to interact with
both NS5A ISDR [70] and HCV E2 [71], thus destabilizing
any E2: NS5A or E2: NS5B interactions, the proposed
underlying mechanism of RH.
As it relates to control of HCV RNA quasispecies, RH is pri-
marily a mechanism regulating transcription. However,
accessory proteins known to alter the processivity and
fidelity of cellular DNA-dependent DNA polymerases [72]
and DNA-dependent RNA polymerase [73], as well as
viral RNA-depended RNA and DNA polymerases (as
reviewed [27]), and the cellular reverse transcriptase, tel-
omerase [74], are strongly conserved in evolution, imply-
ing that ability to vary the fidelity and processivity with
which RNA and DNA are synthesized is a critical and nor-
mal cellular function. The advantages inherent to an abil-
ity to vary RNA sequence and hence protein function or
immunogenicity are obvious, while those conferred by
modulating DNA sequences are less so, at least for coding
regions (in preparation). The cellular analogs of viral
functions controlled by RH – replication, generation of
antigenic diversity (envelope structure), quasispecies
expansion and so forth – may therefore be modulated by
similar mechanisms, and mediated by ancestrally-related
molecules, acting on cellular polymerases to exert control
over cellular quasispecies (e.g. the liver cells) by modulat-
ing cell division, differentiation and expression of cell-sur-
face proteins (Figure 4). The common ancestral origins
and possible structural similarities of the proteins that
mediate RH in viruses and those that modulate polymer-
ase functions in cells suggests an obvious mechanism by
which the envelope proteins of HCV, an RNA virus inca-
pable of integration within genomic DNA, HBsAg and
other similar viral envelope proteins, might trigger malig-
nant transformation in hepatocytes to cause HCC (in
preparation), by interference with these accessory
polymerase molecules, thus destabilizing cellular
polymerases. Could it be malignancy is an incidental con-
sequence of the competition between self-replicating mol-
ecules?
8.0 Clinical importance of viral load and genetic 
diversity
It is well established that patients with low initial viral
load, commonly defined as <800,000 IU ml-1  [26],
respond better to therapy than those with high viral loads
[3,44-46]. For example, when patients with HCV geno-
type 1 were treated with pegylated interferon 2∝ (PEG-
IFN∝) and ribavirin for 48 weeks [3] 56% of those with
low baseline viraemia, defined in that study as <2 × 106
copies ml-1, developed SVR compared to 41% of those
with high base-line viraemia, defined as >2 × 106 copies
ml-1. These viral load-dependent differential responses are
seen across genotypes [3,39] and have been reported in
both treatment naïve patients and in patients receiving
PEG-IFN∝ plus ribavirin (RBV) after failing treatment
with combination standard IFN∝ plus RBV or IFN∝ mon-
otherapy [75]. Similarly, high genetic and quasispecies
diversity predicts poorer outcome with therapy [47,49].
However, the influence of initial viral load on response to
therapy is extremely unlikely to be due to high absolute
concentrations of virus per se and is much more likely due
to the underlying reason(s) why viral load is high in the
first place; After all, the distinction between a high viral
load (>8 × 105 IU ml-1) and a low viral load (<8 × 105 IU
ml-1) is entirely arbitrary, differentiation between
responders and non-responders is not defined by any spe-
cific viral load, and the absolute difference between high
and low levels is completely inconsequential when com-
pared to the 4–5 log fall in HCV RNA that will occur if
therapy is effective. What determines viral load?
Replicative homeostasis predicts, in general, that viral
load will be high in patients with viral strains that have
high affinity Envwt:RNApol interactions that RH postulates
increase polymerase processivity (while reducing fidelity),
thus resulting in a high set-point of the replicative equilib-
rium. Patients with these viral strains, therefore, will have
– and by the same mechanism – both high-level basal
viral replication and increased quasispecies complexityVirology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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and diversity compared to strains where Envwt:RNApol
interactions are less high-affinity. As RH predicts that
mutant viral envelope proteins (Envmt) normally act to
decrease RNApol processivity (and increase fidelity), while
interferon or/and interferon-induced endogenous cellular
effector proteins like PKR act to reduce viral replication by
interference with normal Envwt:RNApol interactions, thus
reducing RNApol processivity, and that these interactions
with RNApol occur at the same binding site(s), probably
the thumb domain of nonstructural (NS) region NS5B
and the interferon sensitivity-determining region (ISDR)
in NS5A. Replicative homeostasis predicts that those virus
strains with poor prognostic characteristics (high basal
load and broad quasispecies diversity) will be resistant to
therapy because exogenously administered inhibitors
(IFN) or/and their effector molecules like protein kinase
(PKR) are less easily able to disrupt the high affinity
Envwt:RNApol interactions that cause these adverse viral
characteristics to develop. As a corollary, RH would pre-
dict mutations within this region would reduce the affin-
ity of any Envwt:RNApol interactions, thus reducing viral
load, and rendering them more susceptible to interferon
therapy, a hypothesis confirmed experimentally [76,77].
Furthermore, and by the same mechanism, RH predicts
some mutations involving Env:RNApol interaction sites
may actually increase viral replication, thus explaining the
usually transient increase in HCV RNA levels observed in
some therapeutic trials [76,78,79]. This phenomenon has
been reproduced in-vitro for HIV [80,81], Semliki Forest
virus [82] and probably HBV [83], where mutations
within envelope sequences have been demonstrated to
cause increased viral replication, presumably due to
Cellular correlates of RH Figure 4
Cellular correlates of RH. Accessory proteins that alter the processivity and fidelity of both cellular DNA-dependent DNApol 
(A) [72] and DNA-dependent RNApol (B) [73], as well as viral RNA-depended RNApol and DNApol (C), and the cellular reverse 
transcriptase telomerase (D) [74], are strongly conserved in evolution suggesting modulation of both the fidelity and rate of 
replication of cellular RNA and DNA may be important under some circumstances.
+ +
+ +
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abnormal Env:RNApol  interactions, as previously dis-
cussed [27]. Finally, a relationship between viral load and
HCV genotypes has been reported by some [84,85] (and
was apparent with small numbers in an early publication
[34], (but not all [86]) workers further suggesting the
mechanism(s) that maintain genotype and determine
viral load may be linked, as RH implies.
In other words, the adverse prognosis patients with high
viral load and quasispecies diversity experience with cur-
rently available treatments is an innate consequence of
the replicative equilibrium intrinsic to those viral strains,
rather than absolute viral load or level of quasispecies
diversity per se. Of course, as a secondary consequence,
the associated broad antigenic diversity generated by the
replicative equilibrium of these viral strains will also
impair immune-mediated clearance of infected cells.
9.0 Acute hepatitis C
Accurate diagnostic tests for HCV have dramatically
improved the safety of transfusion medicine and caused
acute HCV to be an increasingly uncommon clinical
entity, however, when it does occur, chronic viral persist-
ence and liver disease develops in 50–80% of patients
[26]. Treatment of acute HCV is characterised by very high
response rates and rapid clearance of HCV RNA from
serum [87-89], with Jaeckel et al., reporting a 98% end of
treatment response (not SVR) and clearance of HCV RNA
from serum by 3.2 weeks when treatment was begun, on
average, 89 days after infection occurred [87]. This same
group (although slightly different patient cohort) report-
ing an SVR of 89% after 24 weeks off therapy [88], a sig-
nificantly better outcome than one might predict
considering the distribution of genotypes treated.
Although some of this apparent improvement in outcome
with treatment of acute HCV is due to the ancient artefact
of immediate intervention (tacitly acknowledged by Sant-
antonio et al., [89]) that physicians have benefited from
for millennia – if the natural history of disease X is that
50% of acute cases resolve spontaneously, and the other
50% go on to develop chronic disease, and treatment Y
cures 50% of chronic cases but has no impact on whether
acute disease resolves, then administration of Y to all cases
in the acute phase will result in "cure" of 75% of cases
overall, of which only 25% are properly attributable to Y,
with the other 50% expected anyway – there seems little
doubt treatment of acute HCV does actually improve out-
comes. The reasons for this are not clear, but one hypo-
thesis put forward is that during acute HCV the virus has
not yet fully deployed its impressive anti-cell-defence arse-
nal that Gale and co-workers [20,90-93] and others [71]
have so elegantly dissected. While this explanation cer-
tainly sounds plausible, (though it does raise the obvious
question: "If so, why can't the innate cellular mechanisms
clear virus during this window of opportunity?") and is
possibly even true, it is not supported by viral kinetic data;
During acute infection HCV viraemia, and therefore viral
RNA and protein concentrations, rise rapidly to peak by
about week 12 at about 107–8 copies HCV RNA ml-1, then
fall by ~2 logs to 105 copies HCV RNA ml-1 long-term (Fig-
ure 5) [94,95]. Therefore, during acute infection (e.g.
point A, Figure 5), the viral anti-cell-defence molecules
(presumably mostly proteins, but possibly also ribozymes
and small interfering RNAs) are present in concentrations
at least 2 logs higher than seen during chronic infection
(e.g. points B to C, Figure 5) suggesting, in fact, that treat-
ment of HCV during the acute phase should be less effec-
tive treatment of chronic infection. It obviously isn't. Of
course, it may be that the "quality" of these viral anti-cell
defence molecules isn't optimal during acute disease
(Why?) or that they haven't had time to neutralize innate
cellular defences (How long does cleavage of Toll-like
receptor 3 by HCV NS3/4A proteases etc., take?), or some
other reason, but the "failed cell neutralization" hypo-
thesis, as it relates to acute infection at least, is unsup-
ported by current data. A different explanation might be
that the RNA polymerase is unstable early (it is certainly
highly processive, and as argued previously, replicating
less faithfully than it does long-term [15]), because the
Env:RNApol interactions RH predicts have not yet evolved
to mature stability, thus rendering the replicative equi-
libria more susceptible to agents like interferon and riba-
virin that RH postulates to act by further destabilizing
them. Parenthetically, whatever the correct explanation,
the apparently enhanced efficacy of therapy for acute HCV
is strong evidence that the absolute level of viraemia, per
se, is not an important determinant of treatment out-
come, as suggested above.
10.0 Mechanisms of antiviral drug action
10.1 Interferon
The interferon family, including the type 1 IFNs interferon
-∝, β, ω, and λ, have diverse and intricate intracellular
functions, including roles in lipid metabolism, apoptosis,
and inflammatory responses [96], mediated physiologi-
cally by interferon stimulated genes (ISGs) that include
Janus activated kinase (Jak1), signal transducer and activa-
tor of transcription proteins 1 and 2 (STAT1/2) and tyro-
sine kinase 2 (Tyk 2) [97,98] that combine to create a
hostile intracellular anti-viral milieu [99,100]. The result-
ing antiviral state is both virus-independent and highly
complex; for example, while the 2–5 oligoadynlate syn-
thetase and protein kinase are induced by IFN [69], and
have significant antiviral activity [101,102], the antiviral
activity of IFN is independent of either enzyme [101].
In a recent review of the actions of interferon and ribavirin
[26] the authors state "Interferon-∝ has potent antiviral
activity but does not act directly on the replication com-Virology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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plex" without citing reference or data to support that
assertion. Apart from the philosophical difficulties associ-
ated with proving an event does not occur, demonstration
of this direct non-effect in either in-vitro or in-vivo would
be extremely difficult, particularly as recent crystallo-
graphic evidence suggests inhibitors of HCV RNApol can
change the enzyme irreversibly to the inactive conforma-
tion [103], raising the possibility any putative interferon-
polymerase interactions may need only be transient to
exert their effect(s). Moreover, while exogenously admin-
istered IFN appears to interact with same cellular receptors
and act through the same pathways as endogenous IFN, it
is by no means certain that pharmacological doses of IFN
won't also act in other ways or have more direct antiviral
effects. Furthermore, a direct inhibition of the HCV repli-
cative apparatus by IFN-∝, but not ribavirin, has been
clearly demonstrated in the replicon system confirming
the virus itself and not necessarily only the immune sys-
tem is a direct target of IFN action [104]. Nevertheless,
clear evidence indicates secondary effector mechanisms
such as protein kinase R [102] mediate, at least in part, the
antiviral effects of IFN, and that the known molecules
with which PKR interacts include both HCV E2 protein
[71] – the region of HCV envelope most likely to mediate
RH [61] – and the non-structural NS5A [92] gene product
– the putative interferon sensitivity-determining region
(ISDR) – known to effect both viral load and IFN response
[64] and postulated to be the other interactive region
mediating RH. In a purely pragmatic sense it may not
much matter whether the molecule(s) that disrupt the
putative Env:RNApol interactions – the Replication Modu-
lating Elements (RMEs) – postulated in RH is interferon
directly or/and PKR binding to either Env or RNApol or
some other as yet unidentified effector ligand(s), as both
regions are highly genotype constrained, (heterotypic gen-
otype 1a NS5A protein, for example, being non-func-
tional in genotype 1b NS5A expression system [19]), the
outcome will be a genotype-dependent interference with
RNApol processivity and fidelity, as RH predicts (Figure 6).
10.2 Ribavirin
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxy-
amide) is a purine (guanosine) analogue phosphorylated
within cells to ribavirin mono-, di- and triphosphate
(RMP, RDP and RTP, respectively). Ribavirin triphosphate
pairs equally efficiently with either uridine (U) or cytidine
(C) and is incorporated into nascent RNA strands by viral
RNA polymerases without causing chain termination
[105,106] but its incorporation into RNA opposite U or C
is highly inefficient and proceeds at ~2 × 10-5 of the rate U
Kinetics of HCV infection Figure 5
Kinetics of HCV infection. HCV replication increases rapidly to peak at ~107 copies HCV RNA ml usually by week 12 (A) 
before falling to ~105 long term. Concentration of virus anti-cell-defence molecules therefore maximal during acute phase 
infection and ~102 greater than chronic phase (B to C).
0
10
 1
10
 2
10
 3
10
 4
10
 5
10
 6
10
 7
10
 8
1000
100
10
0
Time post infection
Months Years 0 2 4 6 8 10 12 14 Weeks
S
e
r
u
m
 
[
H
C
V
]
 
 
v
i
r
i
o
n
s
/
m
l
H
e
p
a
t
i
c
 
I
n
j
u
r
y
 
(
 
A
l
t
 
u
/
l
 
)
A
B CVirology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
Page 12 of 23
(page number not for citation purposes)
Conceptual schematic of genotype-specific interferon action Figure 6
Conceptual schematic of genotype-specific interferon action. (A) Normal HCV replication (genotype 2, for example) with con-
sensus-sequence envelope (E2) and P7 proteins (blue) tightly interacting with NS5B RNApol (green) RNApol causing normal 
rapid low-fidelity replication and synthesis of a normal viral RNA quasispecies. (B) Interferon treatment results in either inter-
feron or/and PKR binding to NS5B or E2 abrogating normal Env:RNApol interactions hence altering RNApol conformation 
resulting in synthesis of higher fidelity RNAs at lower rate. (C) Normal HCV replication (genotype I) with consensus sequence 
envelope proteins (blue) also tightly interact with RNApol (green), to produce a normal viral RNA quasispecies (C), but the dif-
ferent NS5B or E2 (P7) binding site topology results in less efficient RNApol inhibition (D) by interferon or/and PKR compared 
to genotype 2.
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or C are incorporated opposite ribavirin, significantly
slowing chain elongation [106].
A recent review of ribavirin action [26] suggested four
main mechanisms of ribavirin action; i) Immunomodula-
tion, promoting TH1 helper over TH2 lymphocyte pheno-
types [107] ii) GTP depletion by inhibition of IMPDH
[108] iii) Direct inhibition of RNA polymerase and iv)
Mutagenesis causing EC or massive loss of genetic infor-
mation resulting in reduced viral infectivity [109], to
which has been added v) Inhibition of RNA capping
[110]. However, empirical evidence of multiple different
types strongly suggests mechanisms (ii-v) are untenable
(by themselves), while the mechanism(s) mediating
immunomodulation are unclear. Depletion of intracellu-
lar GTP pools can be dismissed as an important mecha-
nism for several reasons; First, addition of excess
guanosine only partially restores inhibition of HCV repli-
cation by ribavirin [111]. Second, potent inhibitors of
IMPDH including mycophenolic acid and VX492 have
had either little effect on HCV replication in patients, or
an effect that is guanosine independent [112]. Third, as
Maag et al point out [106], the low apparent binding con-
stant Kd, app of HCV RNApol for GTP make it highly
unlikely that the enzyme would be sensitive to the 2 fold
reduction in GTP levels that occurs when cells are treated
with ribavirin [113]. Direct inhibition of HCV polymerase
and cap-inhibition are also unlikely to contribute greatly
to the antiviral effect of ribavirin; while ribavirin is known
to inhibit to several viral polymerases directly, the concen-
trations required (40–150 mM) [106,114,115] are much
higher than the concentrations of ribavirin (~10 mM)
normally attained clinically [116], while HCV replication
is cap-independent.
A more fundamental problem is that mechanisms (ii-v)
cannot account for the observed effect of ribavirin on
HCV clearance kinetics (Figure 1). Hepatitis C replication
is extremely rapid with ~1012 virions typically generated
and cleared daily, and each virion having a half-life (t1/2)
of about 2.7 hours [117]. Mechanisms effectively targeting
viral genomic replication (such as ii-v), viral protein syn-
thesis or virion assembly would be expected to cause sig-
nificant changes in the first-phase viral kinetics. While
ribavirin unquestionably causes transient reduction in
HCV levels in some patients [78] (Figure 1), these changes
are unimpressive, and the clinically important effects of
ribavirin are to accelerate the phase 2 fall in HCV RNA
[117-120], thought to reflect immune-mediated clearance
of infected cells, and to reduce relapse rates at the end of
treatment [121,122].
The effect of ribavirin therapy on HCV dynamics was
recently carefully re-evaluated leading the authors to state:
"Ribavirin exerts a significant, moderate and transient
antiviral effect in a significant proportion of patients"
[78]. The effect of ribavirin demonstrated was certainly
transient, generally lasting less than 3 days, and occurred
in 4/7 patients, but was, at best, modest (when compared
to the effects of interferon [117,120,123]) with ~0.8 log
fall (0.5, 0.5, 0.6, 1.5, from the graphs) of HCV RNA. Fur-
thermore, in those patients in whom there had been a fall
in viraemia, HCV RNA rebound of HCV RNA to pre-treat-
ment levels (and beyond, patient B2) occurred within 4
days. Moreover, just as many of the patients (4/7, patients
B2, B3, B5, B6 reported by Pawlotsky et el., [78]) experi-
enced a transient increase (although this was less than the
decrease seen in 'responding' patients; +0.15, 0.17, 0.2,
0.25 logs, from the graphs) in HCV RNA during the initial
4 days. The rebound viraemia – a phenomenon that has
reported before for ribavirin [124], interferon alone
[76,79] and combination PEG-IFN/ribavirin [125] treat-
ment of HCV – was unexplained and the observed slight
increase in HCV RNA was neither explained nor com-
mented on. A moments thought would strongly suggest
the rebound increase in HCV RNA typically seen by day 4
of ribavirin monotherapy occurring (Figure 1), as it does,
when ribavirin concentrations are steadily increasing [78],
like the increase in HCV RNA seen in partial responders
occurring during interferon and combination PEG-IFN/
ribavirin therapy, must be mediated by some compensa-
tory viral homeostatic mechanism.
10.2.1 Error Catastrophe
While this paper is not meant as a detailed critique of EC
theory as it supposedly relates to clinical viral infections,
the mathematical models [126] used to promote EC con-
tain several critical and implausible underlying assump-
tions (see Summers and Litwin for a rigorous mathematic
treatment of this point [127]), notably i) the idea that all
defective genomes will continue to replicate at a signifi-
cant non-zero rate – thus providing a substrate for further
rounds of defective viral replication and, hence, further
accelerating loss of genetic information beyond that lost
due to the original mutations themselves – thus inexora-
bly diluting consensus (fit) genomes, and ii) that those
consensus sequences that develop any mutations at all
will replicate ineffectively. Neither assumption is likely to
be true; empirical observations suggest that about 40% of
single-hit random mutations will be lethal to RNA viruses
and cause genome extinction, while 30% will be deleteri-
ous but non-lethal and about 1% may actually enhance
replicative fitness [128].
Error catastrophe is clearly completely untenable as an
explanation for the antiviral action of ribavirin when used
to treat HCV; if progressive mutagenesis due to ribavirin
caused EC then it should be highly effective as mono-
therapy. It isn't [129], and this fact, and the fact ribavirin
is incorporated into HCV RNA and known to cause muta-Virology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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genesis [105], is powerful evidence against EC as a mech-
anism of ribavirin action or even as a phenomenon that
affects real viruses in-vivo, as opposed to mathematical
models replicating in-silico. In fact, the ineffectiveness of
interferon as monotherapy for HCV reveals a major para-
dox that further profoundly undermines EC empirically;
As ribavirin is incorporated into the replicating HCV
genome (at a rate of about 1 ribavirin molecule/7000
bases or ~1 molecule/genome for each cycle of replication
[106]) and about 40% of all single mutations are lethal
for RNA viruses [128], one might predict that after 24
hours exposure to ribavirin, or about 8 virion half-lives
[117], HCV RNA levels would fall to < (1-0.4)8 or ~0.017
pre-treatment levels. They obviously do not. The fact that
HCV levels are essentially unchanged by long-term ribavi-
rin therapy despite replicating in increasing concentra-
tions [78] of ribavirin is a critical observation that implies
i) HCV RNApol develops relative and general resistance to
ribavirin incorporation, distinct from the specific resist-
ance conferred by HCV RNApol mutations found in some
HCV isolates [130], ii) the processivity HCV RNApol must
actually increase to compensate for the massive loss of
non-viable genomes that replication in the presence of
ribavirin should produce and iii) that fit genomes (~con-
sensus sequence) are highly preferentially replicated.
Obviously, points ii) and iii) are strong arguments against
EC and in favour of RH.
Even if the assumptions underpinning the theoretical
basis of EC for eukaryotic viruses weren't highly dubious,
the primary empirical observation commonly taken as
proof EC exists as a phenomenon – namely, the loss of
infectivity of viruses serially passaged in the presence of
mutagens such as ribavirin [109] – has several other pos-
sible explanations, including, but not limited to, direct
inhibitory effects of the viral protein quasispecies [15]
generated from the mutated viral genomes that result and
RH per se, as previously discussed [27]. In this regard, the
finding that co-transfection of pre-mutated Foot and
Mouth Disease Virus (FMDV) with wild-type genomes
delayed development of virus production for up to 30
hours (but un-mutated, unrelated and subgenomic RNAs
had no effect) in a dose-independent fashion [131] is crit-
ical and strongly implies the inhibitory effect was medi-
ated by mutated proteins, as RH predicts [27]. The
obvious experiment, co-transfection of wild-type viral
genomes with subgenomic RNAs capable of generating
specific wild-type or mutant viral proteins, especially
envelope [27], and identical control RNAs without pro-
motors or containing frame-shift mutations would
resolve this issue, and further, define sequences that might
be used to generate therapeutic vaccines. Finally, and
while negative results cannot prove the absence of an
effect, when experiments have been conducted specifically
to examine for evidence of EC induced genomic hypermu-
tation, none has been found [132].
10.3 Interferon-ribavirin synergy
Interferon and ribavirin are clearly synergistic in their
action and this is unexplained. Used initially as mono-
therapy, alpha-interferon was extremely disappointing
with sustained viral response rates (SVR) of 6–12% after 6
months therapy and just 16–20% if therapy was contin-
ued for 12 months [133,134]. Ribavirin is even more dis-
appointing, and virtually no useful antiviral response has
been demonstrated long term [129] when ribavirin is
used as monotherapy to treat HCV [135,136]. By contrast,
treatment with PEG-IFN∝ and ribavirin will result in sus-
tained viral response rates (SVR) of 80–90% after 6
months therapy for HCV genotypes II [36-38] while ~50%
of patients with genotype I [3,35], or over double the rate
for IFN alone, will experience SVR after 48 weeks PEG-
IFN∝ and ribavirin. Paradoxically, despite having little
impact on HCV RNA levels, ribavirin does improve serum
alanine aminotransferase (ALT) levels in a significant
number of patients, with about 30% of patients normaliz-
ing their ALT after 24 weeks ribavirin monotherapy and
some improvement in ALT levels in 55% [135-138], an
observation difficult to reconcile with the notion ribavirin
acts as a direct immunomodulator; if ribavirin does alter
the CD4+ lymphocyte TH1/TH2 subset balance [139,140]
to favour a TH1 response an increased cell-mediated
immune response with enhanced clearance of infected
cells and an increased ALT might be expected.
A coherent explanation of the mechanism(s) of ribavirin
action must, therefore, account for i) transient reduction
in HCV RNA in a proportion of patients ii) rebound
increases in HCV RNA by day 4 in these patients iii) tran-
sient, smaller increases in HCV RNA in a similar propor-
tion of patients and iv) the long term alteration to phase
2 kinetics presumably related to enhanced immune-medi-
ated clearance of infected hepatocytes and v) the synergis-
tic effect of ribavirin and interferon.
In fact, RH predicts and explains all of these observed phe-
nomena (Figures 7, 8, 9); Initially, ribavirin is readily
incorporated into nascent strands of HCV RNA, albeit at a
lower rate than normal nucleotides by HCV RNApol, slow-
ing viral replication and causing RNA mutagenesis as both
a direct consequence of ribavirin incorporation but also
by destabilizing incorporation of canonical bases causing
preferentially A-to-G and U-to-A mutations [130] as well
as mutations in complimentary genomes subsequently
replicated against these parental templates. The initial fall
in HCV RNA levels then has both direct and indirect
causes, although if ribavirin is incorporated at a rate of
only 1:7000 bases (~1 ribavirin molecule/genome) the
direct impact of ribavirin on slowing HCV RNApol proces-Virology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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sivity is likely to be low. Once mutated HCV RNA is trans-
lated, however, RH predicts mutations to the cognate
HCV proteins will have significant effect on the RNApol
processivity: Alteration to wild-type HCV Env will abro-
gate the stimulatory HCV Envwt:RNApol  interactions
hypothesised to occur under RH, thus significantly reduc-
ing RNApol processivity, while the accumulation of HCV
Envmt  will increase the putative inhibitory HCV
Envmt:RNApol interactions, further reducing processivity,
but increasing HCV RNApol fidelity (Figure 7, 8).
Increased HCV RNApol fidelity has two immediate effects.
First, it is known to increase RNApol nucleotide selectivity
[141] and enhanced discrimination against mutagens like
ribavirin and 5-azacytidine [142], and thus conferring rel-
ative resistance of HCV RNApol to ribavirin (thereby par-
tially resolving the ribavirin paradox), hence reducing the
both direct inhibitory effect of ribavirin on HCV RNA syn-
thesis and the rate ribavirin is incorporated into HCV
RNA. This latter effect then reverses the altered HCV
Env:RNA interactions that occurred initially, increasing
Envwt:RNApol interactions and again increasing proces-
sivity, returning the equilibrium back towards pre-treat-
ment state. Together, these compensatory homeostatic
changes can account for result in the rebound of replica-
tion seen with ribavirin monotherapy by day four [78].
Second, as argued previously [15] and expounded below,
the increased HCV RNA polymerase fidelity will reduce
the genetic variability of RNA replication and, conse-
quently, the heterogeneity of viral proteins synthesised,
restricting the antigenic diversity of viral proteins
expressed the cell-surface membranes of infected cells,
thus allowing a more focussed and effective immune
response (Figure 9).
10.3 Interferon/ribavirin immunomodulation
Both interferon and ribavirin are held to have immunos-
timulatory or immunomodulatory actions. However, like
Postulated mechanism of ribavirin action under RH Figure 7
Postulated mechanism of ribavirin action under RH. Translation of normal viral quasispecies RNAs (panel A) result in normal 
Envwt: Envmt concentrations of distribution and normal Env:RNApol interactions resulting in normal rapid low-fidelity replication. 
Incorporation of ribavirin (, panel B) into viral RNAs and subsequent translation of excess mutated Envmt viral proteins, caus-
ing abnormal relative Envwt: Envmt concentrations and Env:RNApol interactions dominated by Envmt:RNApol interactions that 
cause increased RNApol fidelity and reduced processivity.
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all fervently held beliefs, it is worth asking whether or not
this is actually true, and whether these terms help our
understanding of how these important drugs work. As dis-
cussed above there is no doubt IFN has profound effects
on the innate intracellular antiviral responses. There is
also no doubt interferon therapy can result in HBeAg--
>anti-HBeAb [143] and occasionally HBsAg-->anti-
HBsAb seroconversion [144] and cause clearance of HCV
from serum even when used as monotherapy [3]. Inter-
feron is also associated temporally with development or
exacerbation of autommune diseases [145,146]. When
administered to HCV infected patients, ribavirin induces
an early immune response by peripheral blood CD4+ T
cells [140], as well as altering the T helper (Th) 1/TH2 sub-
set balance [139]. However, are these effects necessarily
primarily mediated by direct "immune stimulation"?
Administration of HBsAg as vaccine also results in devel-
opment of anti-HBsAb, and when administered as thera-
peutic vaccine to patients with chronic HBV caused HBV
DNA clearance in 18 of the 32 patients [147], while case-
controlled studies of HBV vaccination have demonstrated
greatly increased risk (odds ratios 5.6, 9.1 and 18) for the
development of "autoimmune" diseases [15], including
Homeostatic response to ribavirin (R) action Figure 8
Homeostatic response to ribavirin (R) action. (A) Initial replication in presence of R () results in increased HCV RNA muta-
tions (including non-viable and truncated genomes, red) that increase synthesis of Envmt (A1) causing Envmt:RNApol interactions 
to predominate increasing RNApol fidelity and reducing processivity, causing an initial fall in HCV RNA. Increased fidelity causes 
increased discrimination against ribavirin and reduced incorporation of R into RNA (B), then increases synthesis of wild-type 
(consensus sequence) RNA, translation of Envwt (B1) causing Envwt:RNApol interactions to predominate increasing RNApol 
processivity but reducing fidelity returning the equilibrium towards baseline. On average, RNA pol fidelity is increased due to 
effect of ribavirin increasing synthesis of Envmt.
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Schematic conceptual representation of viral RNA (i) and protein (ii) quasispecies and the concentrations of specific viral  polypeptides of that quasispecies (iii) as a dynamic function of polymerase fidelity and the relationship to the threshold of  immunological response (TIR) Figure 9
Schematic conceptual representation of viral RNA (i) and protein (ii) quasispecies and the concentrations of specific viral 
polypeptides of that quasispecies (iii) as a dynamic function of polymerase fidelity and the relationship to the threshold of 
immunological response (TIR). During low fidelity replication (A) the viral genetic and phenotypic diversity of the viral quasis-
pecies is high, resulting in a broad spectrum of viral protein phenotypes with relatively low concentrations of each specific indi-
vidual viral polypeptide sequence (coloured bars). During high fidelity replication (B), perhaps induced by IFN/ribavirin, RNA 
and protein sequences diverge less from the consensus sequence resulting in higher concentrations of individual proteins, par-
ticularly consensus sequences (green bars), that trigger immune responses if their concentration exceeds TIR.
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multiple sclerosis, lupus erythematosus and rheumatoid
arthritis [148]. Is this an immunostimulatory action? This
is certainly immunomodulatory, in the limited and trivial
sense that the immune system is measurably different
after HBsAg vaccination, but is it likely that HBsAg has
fundamentally changed the immune system in a general
way that will persist? Will, for example, HBsAg vaccina-
tion result in a brisker and more robust immunological
response in patients subsequently exposed to other unre-
lated antigens such as those generated by influenza infec-
tion? It is, of course, possible that HBsAg is a non-specific
immunostimulator/immunomodulator that results in
generally enhanced immune responsiveness, including
the generation of specific HBsAb etc., but is much more
likely HBsAb arises because homogeneous HBsAg
polypeptide is presented in an appropriate concentration
and HLA-restricted manner that facilitates a normal and
specific immune response – including synthesis of high
affinity HBsAb in high titre and induction of specific T-cell
responses – to HBsAg (and not other antigens) to develop.
Does administration of IFN or ribavirin heighten immune
responsiveness generally (would, for example, the titres of
anti-HBsAg developing after vaccination with HBsAg be
increased by IFN or does HBsAb develop during IFN treat-
ment of HCV?), or are the virus-specific altered immune
responses seen during treatment of patients with chronic
HBV with IFN contingent on the presence of 'live' replicat-
ing virus? In other words, are the apparent immunomod-
ulatory properties seen with IFN and ribavirin due to these
drugs acting directly on the virus? By what possible mech-
anism(s) could nucleos(t)ide analogues like ribavirin
induce or increase the rate of specific antiviral immune
responses?
Development of humoral or T-cell immunological
responses against antigens requires homogeneous antigen
to be presented in an appropriate immunological context
in sufficient concentration. Dose-finding vaccination
studies [149,150] confirm that a threshold concentration
of viral antigen exists below which appropriate immuno-
logical responses are not generated, suggesting the con-
cept of threshold of immunological response (TIR, Figure
9), a level that is likely to vary between individuals, over
time within individuals and according to the general state
of immune arousal, the nature of the antigen itself, and
the presence of competitor antigens.
Obviously, one determinant of the concentration of viral
antigens is viral load. However, and as previously dis-
cussed [15], the quasispecies nature of RNA and retrovirus
infections, and the relative infidelity of RNA polymerases
generally (for DNA viruses), ensures viruses are incapable
of generating homogeneous antigens comprised of identi-
cal polypeptide sequences. The degree of antigenic heter-
ogeneity of viral protein quasispecies that confronts the
immune system is therefore a function of the level of
genetic heterogeneity of the RNA quasispecies, and that is
a direct function of RNApol fidelity. Accordingly, any anti-
viral therapy that increases RNApol fidelity will restrict the
generation of RNA quasispecies diversity, and as a conse-
quence, antigenic diversity, thereby increasing the likeli-
hood any particular viral polypeptide antigen will exceed
the TIR, thus triggering an effective immunological
response. Abrogation of normal Envwt:RNApol interactions
and increased Envmt:RNApol interactions, as RH predicts
will occur with IFN and ribavirin, will increase RNApol
fidelity thus restricting antigenic diversity hence increas-
ing the probability the TIR will be reached and immuno-
logical recognition and clearance of infected cells will
occur. Empirically, if this explanation is correct, one
would expect the genetic diversity of virus from patients
responding to such treatments to decrease, while that
from non-responsive patients to be unaffected or to
increase, as has been confirmed [47].
If, as has been demonstrated [106,109,114], ribavirin
results in mutagenesis of HCV RNA then increased trans-
lation of mutated envelope proteins, ultimately causing
increased Envmt:RNApol interactions and increased RNApol
fidelity will result. Similarly, if interferon either acts
directly to abrogate Envwt:RNApol interactions, by binding
either directly to NS5B, especially at the thumb domain,
or to Env itself, especially to E2 as we suggested previously
[61], or if its action is mediated by secondary effector mol-
ecules like the protein kinase PKR that interact with NS5A
ISDR [70,151] and/or with HCV envelope protein E2
[71], to abrogate Envmt:RNApol RME interactions, then
increased Envmt:RNApol  RME interactions, increased
RNApol  fidelity, restricted antigenic diversity and
enhanced immune responses will result. Obviously, poly-
morphisms of the reactive sites of these secondary effector
molecules might then explain the reduced effectiveness of
interferon therapy in certain populations [8,120]. Finally,
if ribavirin acts to abrogate Envwt:RNApol interactions by
increasing mutations in Envwt protein RME, reducing their
affinity for the RNApol RME, synergistic enhancement of
the effect interferon has on these interactions would be
expected.
11.0 Conclusions
Replicative homeostasis provides a rational mechanistic
basis for the actions of both ribavirin and interferon that
explains many phenomena observed during treatment of
HCV, including the genotype-specific differences in
response rates, and the adverse impact high pre-treatment
viral load and quasispecies diversity has on treatment out-
come. It also provides a rational explanation for other pre-
viously unexplained phenomena like rebound of HCV
RNA levels seen during treatment with both interferon
and ribavirin, and the transient increased viremia seen inVirology Journal 2007, 4:29 http://www.virologyj.com/content/4/1/29
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some patients receiving ribavirin, and occasionally, inter-
feron. Replicative homeostasis also suggests an explana-
tion for the apparent immunostimulatory effects of
ribavirin (and, by extension, other nucleos(t)ides) and
interferon, and thus, elucidates the enhanced phase 2
clearance of HCV RNA seen during treatment ribavirin.
Ockham's razor would suggest this mechanism makes it
unnecessary to postulate a direct immunostimulatory
mechanism for ribavirin, other nucleosides or interferon
(though, clearly, interferon has other direct effects on
innate intracellular responses), although we do not sug-
gest such action(s) is/are excluded.
It is worth considering the likely characteristics of the
envelope-polymerase interactions postulated to mediate
RH and their implications for drug therapy. First, by defi-
nition, RH is a mechanism by which, in part, viral geno-
type is maintained by genotype-specific envelope-
polymerase interactions. These interactions, therefore,
will be virus genotype and probably virus sub-species-spe-
cific, hence therapeutic vaccines and other ligands capable
of interaction with the viral polymerase and/or envelope
at their RMEs and disrupting normal Env:RNApol interac-
tions will probably be highly genotype-specific and, com-
pared to nucleos(t)ide analogues, have relative lack of
toxicity with a high therapeutic index. However, as a con-
sequence of this specificity, their optimal use may require
viral genotyping. Second, the reactions postulated to
mediate RH result in profound inhibition of viral replica-
tion, at least initially during acute viral infection, making
it likely therapies targeting this homeostatic function of
viruses effectively will be extremely potent. Third, as dis-
cussed above, it is possible drugs or therapeutic vaccines
that disrupt viral RH and reduce RNApol processivity and
increase its fidelity, will restrict viral protein diversity and
cause increased cellular expression of dominant viral
epitopes beyond TIR, increasing the likelihood of an effec-
tive and neutralizing immune response and therefore the
likelihood of permenant viral clearance. Fourth, and
implicit in the above discussion, the nature of RH implies
that the putative Env:RNApol RMEs must be highly con-
served; any conformation other than this would result in
the polymerase unable to recognise and distinguish
between wild-type and mutant envelope motifs, render-
ing the virus unable to recognise, and respond to, delete-
rious unbalanced accumulation of excess mutant or wild-
type virus, as we have suggested previously [61]. It is there-
fore possible that viral resistance to drugs or therapeutic
vaccines targeting these interactions would develop
slowly, if at all. Finally, recombinant polypeptides are rel-
atively cheap to produce, and their infrequent administra-
tion as therapeutic vaccines – as opposed to complex daily
regimens of nucleoside analogues and protease inhibitors
– is relatively simple and, hence, more likely to encourage
compliance, an important therapeutic consideration for
all patients, but especially relevant to third world popula-
tions.
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